Recurrent plasmacytoid lymphocytic lymphoma of the bladder secreting multiple monoclonal and biclonal proteins

Related Experiment Video

Updated: Oct 30, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

F Biancari1, G Lepidini, V D'Andrea

  • 1Third Department of Surgery, University La Sapienza, Rome, Italy.

The Journal of Urology
|February 25, 1998
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...